## LVS: Las Vegas Sands Corp. - XLY: Consumer Cyclical

### Executive Summary

No thesis match: MRS_10 -5.9% below STRENGTH zone (3.0-6.0%); RSI 29 oversold (REVERSION excluded per A/B test). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($58.65)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Las Vegas Sands reports 4.3% Q3 2024 revenue decline; net income falls 21.4%**
- Source: Gambling Insider | 20260107T111122 | Neutral | Relevance: 100%
- Las Vegas Sands announced a 4.3% year-on-year decline in Q3 2024 net revenue to $2.68bn, with net income falling 21.4% to $353m. Despite these decreases and mixed performance across its properties, the company authorized $2bn in future share buybacks and increased its annual dividend to $1.00 per share for 2025. This move reflects a focus on strategic objectives and shareholder returns amidst lower-than-expected hold rates and development-related disruptions.

**2. What to Expect From Las Vegas Sands' Q4 2025 Earnings Report**
- Source: inkl | 20260107T111228 | Bullish | Relevance: 100%
- Las Vegas Sands Corp. (LVS) is anticipated to report strong Q4 2025 earnings, with analysts expecting a 44.4% increase in diluted EPS to $0.78 compared to the previous year. The company's stock has outperformed the S&P 500 and Consumer Discretionary Select Sector SPDR Fund over the past year, driven by strong performances in Macao and Singapore. Analysts currently rate LVS as a "Moderate Buy," projecting an 8.6% upside from current levels.

**3. 22,132 Shares in Las Vegas Sands Corp. $LVS Bought by Kercheville Advisors LLC**
- Source: MarketBeat | 20260105T133930 | Somewhat-Bullish | Relevance: 100%
- Kercheville Advisors LLC has acquired a new stake of 22,132 shares in Las Vegas Sands Corp. (NYSE:LVS) during the third quarter, valued at approximately $1.19 million, despite significant insider selling from executives. Las Vegas Sands reported a strong quarter, exceeding EPS estimates with $0.78 and revenue of $3.33 billion, a 24.2% year-over-year increase. The company's stock shows a strong performance with a 52-week high of $70.45 and a consensus price target of $68.52 from analysts.

**4. A Look At Las Vegas Sands (LVS) Valuation After Recent Mixed Share Price Performance**
- Source: Simply Wall Street | 20260106T082123 | Neutral | Relevance: 98%
- Las Vegas Sands (LVS) has shown mixed short-term share price performance but stronger returns over the past three months and year. Despite recent declines, the stock delivered a 21.34% 90-day return and a 33.39% one-year total shareholder return. The company is currently trading at $64.64, with an estimated intrinsic value of $65.85, suggesting it is trading around its fair value according to analysts, though potential risks like a stalling Macau recovery could challenge this valuation.

**5. Inside Delta's new lounge-style club at Las Vegas's massive Sphere venue**
- Source: Stock Titan | 20260105T170209 | Somewhat-Bullish | Relevance: 64%
- Delta Air Lines has been named the Official Airline Partner of Sphere, marking its entry into the immersive entertainment venue with the Delta SKY360Â° Club. This partnership highlights a shared commitment to innovation and technology, offering guests an elevated lounge experience at live events and Sphere Experiences. Delta SkyMiles members will also gain access to exclusive packages, and Delta will feature branded content on the Exosphere.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Goldman Sachs | $80 | $64 | +25% |
| 2025-12-08 | UBS | $68 | $67 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Goldman Sachs | up | Buy |
| 2025-12-08 | UBS | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 5 ($40.40M) |
| Sells | 16 ($58.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 24.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 6.2% (-2.0%)
- Capital Research Glo: 5.0% (-30.9%)
- Blackrock Inc.: 4.0% (-0.1%)
- Price (T.Rowe) Assoc: 2.2% (-7.8%)
- State Street Corpora: 2.1% (-7.2%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.7% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $58M sold (16 transactions in 90 days).
3. Near-term weakness: 5.5% below SMA50 despite long-term uptrend.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.89 indicates undervaluation relative to growth. Forward P/E 19.3x stretched relative to 9% growth. Quality metrics strong (ROE 66%). Analyst sentiment positive (2 raises, avg +13%, $74 target (+20%)). Institutional flow bearish (8 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $42.2B |
| Beta | 0.96 |
| 52W Range | $30.18 - $70.45 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.89 |
| Forward P/E | 19.3 |
| Current P/E | 21.1 |
| YoY Growth | 9.4% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from -1.3% to -5.9% (-4.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.9pp (needs >3.0% for momentum thesis). Underperforming sector by 5.1pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.21x) but short-term weakness (below SMA20). MACD histogram bearish (-0.63), momentum weakening. RSI oversold at 29, potential bounce setup. OFD pattern: -MTH (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -5.94% (CS: 3) | Weak |
| RSI_14 | 29.2 | Oversold |
| MACD Histogram | -0.63 | Bearish |
| vs SMA20 | 0.934x | Below |
| vs SMA50 | 0.945x | Below |
| vs SMA200 | 1.205x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $61.41
- **Stop Loss:** $58.65 (4.5% risk)
- **Target:** $64.17 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 181
- **Position Value:** $11,115.21
- **Portfolio %:** 11.12%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX at 15.38 sits in the normal range (18th percentile of 52-week) with modest upward drift, while yield curve remains positively sloped (+62bps 10Y-3M) supporting risk assets. Breadth at 59.5% shows healthy participation, though elevated put/call ratio (1.12) suggests some hedging activity. FOMC 20 days out provides runway for current conditions to persist.*

### Earnings

**Next:** 2026-01-28 (Est: $0.75)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.62 | $0.78 | +25.4% |
| 2025Q2 | $0.53 | $0.79 | +48.9% |
| 2025Q1 | $0.57 | $0.59 | +3.8% |
| 2024Q4 | $0.58 | $0.54 | -6.3% |

---
*RULE-based L3 | 2026-01-08 08:02 | MRS_10*